ArticleOncoTargets and therapy2016

Efficacy and safety of adding an agent to bevacizumab/taxane regimens for the first-line treatment of Her2-negative patients with locally recurrent or metastatic breast cancer: results from seven randomized controlled trials.

Xiaoqun Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.